All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

Hematopoietic stem cell (HSC) mobilization is a complex process that involves chemotactic factors, proteases, and adhesive molecules in bone marrow (BM) niches \[[@pone.0179986.ref001]--[@pone.0179986.ref003]\]. There is wide inter-individual variability in response to mobilization, and the outcome is hardly predictable despite several known demographic or clinical risk factors such as the following: age, sex, body mass index (BMI), ethnicity, diagnosis, and extent and duration of prior chemotherapy \[[@pone.0179986.ref004]--[@pone.0179986.ref008]\]. Inter-individual variation of HSC mobilization yield can be explained by a multifactorial model consisting of environmental and multiple genetic factors. Genetic contribution to mobilizing capacity is further supported by the fact that the second mobilization in the same donor typically yields similar results to those from the first mobilization \[[@pone.0179986.ref009],[@pone.0179986.ref010]\].

Previous studies have reported genetic associations between single nucleotide polymorphisms (SNPs) and HSC mobilization yield \[[@pone.0179986.ref011]--[@pone.0179986.ref015]\]. Most of these SNPs are located in gene encoding molecules with known functional significance in the mobilization pathway, including C-X-C motif chemokine ligand 12 (*CXCL12*), vascular cell adhesion molecule 1 (*VCAM1*), CD44 (*CD44*), and colony stimulating factor 3 receptor (*CSF3R*) \[[@pone.0179986.ref011]--[@pone.0179986.ref015]\]. However, some of the results were not replicated in subsequent studies \[[@pone.0179986.ref011],[@pone.0179986.ref016],[@pone.0179986.ref017]\], and the responsible gene remains elusive.

Recent genome-wide association studies have shown that various hematologic traits of white blood cells (WBC), red blood cells, platelets, and CD34+ cells are highly heritable \[[@pone.0179986.ref018],[@pone.0179986.ref019]\]. Previous studies have also indicated that each WBC subtype shares some associations which are probably attributable to shared process of differentiation and maintenance in BM and peripheral blood (PB) \[[@pone.0179986.ref018],[@pone.0179986.ref020]\]. Therefore, we hypothesized that genetic factors associated with WBC count, neutrophil count, and circulating CD34+ cell count could also contribute to the regulation and migration of HSCs in BM niches and in PB.

The aim of this study was to identify genetic factors associated with HSC collection yield after mobilization in Korean population. We also attempted to determine whether our finding could be applied to other ethnic group of European ancestry.

Methods {#sec002}
=======

Participants {#sec003}
------------

A total of 148 Korean subjects, including 56 healthy donors for allogeneic HSC transplantation and 92 patients with hematologic disorders for autologous HSC transplantation, were prospectively recruited for this study. The European set was recruited to confirm the applicability of our findings, and consisted of 101 healthy donors of European ancestry from Germany. This study was approved by the institutional review board (IRB) of the Severance Hospital, Yonsei University College of Medicine (IRB No. 4-2013-0145). Written informed consent was obtained from all participants, in accordance with the Declaration of Helsinki.

Mobilization and HSC collection {#sec004}
-------------------------------

For healthy donors, standard mobilization protocol was used with G-CSF (filgrastim 10 μg/kg daily), and collection was initiated on the fifth day after G-CSF initiation. Mobilization for patients undergoing autologous HSC transplantation was performed using G-CSF only or chemotherapy followed by G-CSF. Apheresis started when the PB leukocyte count reached 3.0 x 10^9^/L after leukocyte nadir, in the case of combination with chemotherapy. Peak circulating CD34+ cell count (/μL), collected just before apheresis, was assessed using a Stem-Kit (Beckman Coulter, Miami, FL, USA) for the Korean set and with a BD Stem Cell Enumeration kit (BD Biosciences, San Jose, CA, USA) for the European set. The CD34+ cell content in the first apheresis product was enumerated in 122 participants in the Korean set, and two additional outcomes were evaluated: total CD34+ cell count per donor body weight (/kg) obtained from the first apheresis; and CD34+ cell count (/μL) from the first apheresis product.

Selection of target polymorphisms in candidate genes {#sec005}
----------------------------------------------------

To determine whether previously reported genetic associations with HSC yield might be applied to Koreans, we selected four common polymorphisms (rs1801157, rs1041163, rs13347, and rs3917924) in the following four genes: *CXCL12*, *VCAM1*, *CD44*, and *CSF3R* \[[@pone.0179986.ref011]--[@pone.0179986.ref017]\]. One polymorphism (rs2680880) in *CXCR4* was not included, as it was not found in East Asians (<http://www.1000genomes.org/>) \[[@pone.0179986.ref012]\]. To identify more candidate genes, we searched the literature for SNPs that are associated with WBC, neutrophil, or CD34+ cell counts \[[@pone.0179986.ref019]--[@pone.0179986.ref028]\] ([Fig 1](#pone.0179986.g001){ref-type="fig"}). Among the 64 additional SNPs, 15 with East Asian minor allele frequency of less than 0.05 were removed. Candidate genes were adopted from the literature or selected based on the functional relatedness to mobilization mechanism, such as cytokines, chemokines, proteases, and adhesion molecules (<http://www.uniprot.org/>) \[[@pone.0179986.ref002],[@pone.0179986.ref003]\]. In total, 53 SNPs were selected for genotyping ([Table 1](#pone.0179986.t001){ref-type="table"}).

![Flow diagram of target polymorphism selection.\
The diagram indicates inclusion and exclusion criteria for selection of target polymorphism.](pone.0179986.g001){#pone.0179986.g001}

10.1371/journal.pone.0179986.t001

###### List of 53 polymorphisms in 33 genes included in this study.

![](pone.0179986.t001){#pone.0179986.t001g}

  rs ID        Chromosome   Location (GRCh38.p2)   Candidate gene   Distance to gene    Protein function
  ------------ ------------ ---------------------- ---------------- ------------------- --------------------------------------------------------------------------------
  rs11121242   1p36.23      8846242                *RERE*           20 kb downstream    Control of cell survival
  rs6577536    1p36.23      8850051                *RERE*           23 kb downstream    Control of cell survival
  rs11590606   1p36.23      8857610                *RERE*           31 kb downstream    Control of cell survival
  rs10864368   1p36.23      8858254                *RERE*           32 kb downstream    Control of cell survival
  rs3917924    1p34.3       36480052               *CSF3R*          Intron2             Cell adhesion and chemotaxis
  rs1041163    1p21.2       100718269              *VCAM1*          1 kb upstream       Cell adhesion and migration
  rs6702883    1p21.1       104700458              intergenic                           
  rs4311917    1p13.3       107183121              *NTNG1*          Intron2             Controlling axon growth
  rs345275     1p13.3       107951181              *VAV3*           Intron1             Regulation of cell adhesion
  rs2365669    1p13.2       111820023              *KCND3*          Intron2             Subunit of potassium channel
  rs7523839    1p13.2       115630459              *VANGL1*         11 kb upstream      Multicellular organism development
  rs850610     1p13.1       116406090              *ATP1A1-AS1*     Exon 3              Non-coding RNA
  rs10923929   1p12         119963373              *NOTCH2*         Intron11            Stem cell population maintenance
  rs11240089   1q21.1       147588715              *BCL2*           Intron1             Cell migration
  rs4657616    1q23.1       159001296              *ACKR1*          202 kb upstream     Chemokine receptor
  rs2518564    1q23.1       159092646              *ACKR1*          111 kb upstream     Chemokine receptor
  rs12075      1q23.1       159205564              *ACKR1*          Exon 2              Chemokine receptor
  rs12740969   1q21.3       154514584              *TDRD10*         Intron4             Nucleotide binding
  rs11264422   1q22         155938032              *RXFP4*          3 kb upstream       Relaxin-3 receptor
  rs1962508    1q23.3       161975629              *DDR2*           655 kb upstream     Cell migration and remodeling of the extracellular matrix
  rs2806424    1q23.3       162721669              *DDR2*           Intron4             Cell migration and remodeling of the extracellular matrix
  rs6426893    1q23.3       165058105              intergenic                           
  rs919679     1q24.1       166287925              intergenic                           
  rs6734238    2q13         113083453              *IL1F10*         7 kb upstream       Cytokine
  rs10932765   2q35         218234761              *ARPC2*          Intron5             Cytoskeleton constituent
  rs16850408   4q13.3       74067090               *CXCL2*          29 kb upstream      Chemokine
  rs546829     4q13.3       74090655               *CXCL2*          6 kb upstream       Chemokine
  rs9131       4q13.3       74097332               *CXCL2*          Exon 4              Chemokine
  rs7667376    4q13.3       74102173               *CXCL2*          2 kb downstream     Chemokine
  rs1371799    4q13.3       74112120               *CXCL2*          12 kb downstream    Chemokine
  rs7686861    4q13.3       74132767               *CXCL2*          33 kb downstream    Chemokine
  rs2517524    6p21.33      31057936               *HCG22*          Intron3             Non-coding RNA
  rs2853946    6p21.33      31279426               *HLA-B*          74 kb upstream      Regulation of immune response
  rs2844503    6p21.33      31474954               *HLA-B*          117 kb downstream   Regulation of immune response
  rs6936204    6p21.32      32249315               intergenic                           
  rs5020946    6p21.32      32482312               *BTNL2*          73 kb downstream    Regulation of T-cell proliferation
  rs4895441    6q23.3       135105435              *MYB*            75 kb upstream      Control of proliferation and differentiation of hematopoietic progenitor cells
  rs12660713   6q23.3       135196858              *MYB*            Intron9             Control of proliferation and differentiation of hematopoietic progenitor cells
  rs976760     7p21.2       14234028               *DGKB*           Intron22            Intracellular signal transduction
  rs445        7q21.2       92779056               *CDK6*           Intron2             Hematopoietic stem cell differentiation and cell adhesion
  rs2163950    8q24.21      129585339              *CCDC26*         Intron 1            Non-coding RNA
  rs579459     9q34.2       133278724              *ABO*            3 kb downstream     Blood group system
  rs1801157    10q11.21     44372809               *CXCL12*         Exon 4              Chemokine
  rs13347      11p13        35231725               *CD44*           Exon 18             Cell adhesion and migration
  rs2183383    11p11.12     50279041               *PTPRJ*          2 Mb downstream     Regulation of cell adhesion
  rs17609240   17q21.1      39954436               *GSDMA*          8 kb upstream       Pyroptosis mediator
  rs3894194    17q21.1      39965740               *GSDMA*          Exon3               Pyroptosis mediator
  rs3859192    17q21.1      39972395               *GSDMA*          Intron6             Pyroptosis mediator
  rs4065321    17q21.1      39987295               *PSMD3*          Intron3             Regulatory subunit of the 26 proteasome
  rs4794822    17q21.1      40000459               *CSF3*           14 kb upstream      Cytokine that controls granulocyte production
  rs8078723    17q21.1      40010626               *CSF3*           4 kb upstream       Cytokine that controls granulocyte production
  rs8065443    17q21.1      40052687               *MED24*          Intron3             Component of transcriptional coactivator complex
  rs2072910    20p12.2      9384656                *PLCB4*          Intron13            Intracellular signal transduction

SNP genotyping {#sec006}
--------------

Genomic DNA was extracted from PB leukocytes using the QIAamp DNA Blood Mini Kit (Qiagen, Venlo, The Netherlands). The primer sequences for polymerase chain reaction (PCR) amplification and sequencing were designed using Primer3 software \[[@pone.0179986.ref029]\]. PCR was performed on 100 ng of genomic DNA, and sequencing was carried out using the BrightDye Terminator Cycle Sequencing Kit (Nimagen, Nijmegen, The Netherlands) on ABI 3500 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). The results were compared with reference sequences using Sequencher 5.1 software (Gene Codes Corp., Ann Arbor, MI, USA). Quality of data was assessed using PHRED score for each base call \[[@pone.0179986.ref030]\]. The threshold for PHRED score was 20, based on the manufacturer's instructions. In case of result with inadequate quality, sequencing was repeated and all genotype of tested locus were determined (no missing genotype data).

Statistical analysis {#sec007}
--------------------

Following the Kolmogorov---Smirnov normality test, natural log transformation was applied on continuous outcome variables with skewed distribution for analysis. The association between continuous variables (age and BMI) and mobilization outcomes (CD34+ cell count in PB, total CD34+ cells/kg, and CD34+ cells in a product) were analyzed using Pearson correlation. The association between categorical variables (sex, diagnosis, BM involvement of disease, chemotherapy regimen history, mobilization protocol, and SNP genotype), and mobilization outcomes were analyzed using an independent two-sample t-test (for two categories) and analysis of variance (for three categories). Three subgroups were established for the genotype of each polymorphism: homozygous for the major allele, heterozygous and homozygous for the minor allele. We also tested three genetic models (dominant, recessive, and additive) using biallelic marker coding. SNPs with a raw *P* \< 0.05 in analysis with all three mobilization outcomes were included in multivariate linear regression analysis. Additional variables related to patient demographics or clinical history with *P* \< 0.05 shown in univariate analysis were included in multivariate analysis. Finally, the following variables were included in multivariate analysis according to each mobilization outcome: 1) CD34+ cell count in PB: sex, diagnosis, chemotherapy regimen history, and rs11264422 (*RXFP4*) genotype; 2) total CD34+ cells/kg: sex and *RXFP4* genotype; and 3) CD34+ cell count in a product: sex, BMI, diagnosis, and *RXFP4* genotype. False discovery rate (FDR) controlling procedure was used to adjust for multiple testing according to the genetic model \[[@pone.0179986.ref031]\]. *P* values \< 0.05 were considered significant, and *P* values \< 0.2 after FDR adjustment were considered to have a tendency \[[@pone.0179986.ref032]\]. Statistical analysis was performed using SPSS Statistics version 23.0.0 (IBM Corp., Armonk, NY, USA). FDR adjusted *P* values were calculated using Microsoft Exel 2010 (Microsoft Corporation, Redmond, WA, USA).

Results {#sec008}
=======

Patient characteristics {#sec009}
-----------------------

Patient characteristics are summarized in [Table 2](#pone.0179986.t002){ref-type="table"}. The group consisted of individuals who were diagnosed with acute leukemia (n = 8), non-Hodgkin lymphoma (n = 50), multiple myeloma (n = 33), and sarcoma (n = 1). On the first day of apheresis, the median circulating CD34+ count was 44 cells/μL in the Korean set and 93 cells/μL in the European set (healthy donors only for the latter).

10.1371/journal.pone.0179986.t002

###### Characteristics of the participants in this study.

![](pone.0179986.t002){#pone.0179986.t002g}

                                        n (%)/median (interquartile ranges)   
  ------------------------------------- ------------------------------------- -------------------
  No.                                   148                                   101
  Age (yr)                              46 (32--56)                           32 (26--42)
  Sex                                                                         
   Female                               63 (42.6)                             26 (25.7)
   Male                                 85 (57.4)                             75 (74.3)
  Body-mass index (kg/m^2^)             24.4 (21.5--26.1)                     24.5 (22.4--28.0)
  Diagnosis                                                                   
   Healthy donor                        56 (37.8)                             101 (100)
   Acute leukemia                       8 (5.4)                               \-
   Non-Hodgkin lymphoma                 50 (33.8)                             \-
   Multiple myeloma                     33 (22.3)                             \-
   Sarcoma                              1 (0.7)                               \-
  BM involvement of disease                                                   
   Present                              51 (34.5)                             \-
   Absent                               97 (65.5)                             \-
  Chemotherapy regimen history                                                
   Multiple regimens (three or more)    9 (6.1)                               \-
   One or two regimens                  139 (93.9)                            \-
  Mobilization                                                                
   Chemotherapy and G-CSF               80 (54.1)                             \-
   G-CSF only                           68 (45.9)                             101 (100)
  CD34+ cell count (/μL) in PB          44 (22--84)                           93 (67--116)
  First apheresis product\*                                                   
   CD34+ cell count (/μL)               1,418 (591--2,330)                    \-
   CD34+ cell count/kg donor (×10^6^)   3.54 (1.69--6.91)                     \-

PB, peripheral blood

^a^CD34+ cell count in an apheresis product was measured in 122 participants.

Relaxin/insulin-like family peptide receptor 4 {#sec010}
----------------------------------------------

Of the 53 SNPs, only one polymorphism (rs11264422) made a significant difference in the three HSC mobilization outcomes of the Korean set ([Table 3](#pone.0179986.t003){ref-type="table"}). The rs11264422 genotype, located 3 kb upstream of the relaxin/insulin-like family peptide receptor 4 (*RXFP4*) gene, was significantly associated with circulating CD34+ cells/μL (raw *P* = 0.03), total CD34+ cells/kg (raw *P* = 0.008), and product CD34+ cells/μL (raw *P* = 0.003) ([Fig 2](#pone.0179986.g002){ref-type="fig"}). Three patients (two with lymphoma and one with multiple myeloma) who were homozygous for a minor allele (AA genotype) showed remarkably higher mobilization outcomes compared to both the 25 patients who were heterozygous (TA genotype) and the 120 who were homozygous (TT genotype) for the major allele. Moreover, the presence of A allele (TA+AA genotypes) showed significant association with higher CD34+ cells/μL in a product (raw *P* = 0.02). Superior mobilizers (defined as \> 200 circulating CD34+ cells/μL) had the highest frequency (66.7%) of the AA genotype, followed by TA (12.0%) and TT (5.8%) genotypes ([Fig 3](#pone.0179986.g003){ref-type="fig"}). In contrast, poor mobilizers (defined as \< 20 circulating CD34+ cells/μL) had a higher frequency of the TT (25.0%) than TA (12.0%) genotype. However, for rs11264422 genotyping using the European set, the circulating CD34+ cell count did not differ between each genotype subgroup. SNP was at Hardy---Weinberg equilibrium in both Korean and European sets.

![Correlations between rs11264422 genotype and continuous outcomes.\
There were significant associations between rs11264422 genotype and (A) circulating CD34+ cells/μL (raw *P* = 0.03), (B) total CD34+ cells/kg (raw *P* = 0.008), and (C) product CD34+ cells/μL (raw *P* = 0.003) in the Korean set (gray-colored bar). However, no statistically significant association was found between rs11264422 genotype and circulating CD34+ cells/μL in the European set (solid-lined bar). Mobilization outcomes were applied natural log transformation, due to the skewed distribution.](pone.0179986.g002){#pone.0179986.g002}

![The rs11264422 genotype distribution of participants in the Korean set, classified by circulating CD34+ cell count.\
Superior mobilizers (\> 200 cells/μL) had 66.7%, 12.0%, and 5.8% frequency rates in AA, TA, and TT genotypes, respectively. Poor mobilizers (\< 20 cells/μL) had 25.0% and 12.0% frequency rates in TT and TA genotypes, respectively.](pone.0179986.g003){#pone.0179986.g003}

10.1371/journal.pone.0179986.t003

###### Association of rs11264422 with mobilization outcomes[^a^](#t003fn002){ref-type="table-fn"}.

![](pone.0179986.t003){#pone.0179986.t003g}

  Genotype   Korean set   European set                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  ---------- ------------ -------------- --------------------------------------------------------------------------------- --------------------------------------------- ----- ------------- ----------------------------------------------------------------------------------- --------------------------------------------- ----- ------------- ---------------------------------------------------------------------------------- -------------------------------------------------------------------------------------- ---- ------------- -------------------------------------------
  TT         120          3.60 ± 1.28    0.03[^b^](#t003fn003){ref-type="table-fn"}[\*](#t003fn005){ref-type="table-fn"}   0.808[^b^](#t003fn003){ref-type="table-fn"}   98    1.11 ± 1.33   0.008[^b^](#t003fn003){ref-type="table-fn"}[\*](#t003fn005){ref-type="table-fn"}    0.424[^b^](#t003fn003){ref-type="table-fn"}   98    7.10 ± 1.39   0.003[^b^](#t003fn003){ref-type="table-fn"}[\*](#t003fn005){ref-type="table-fn"}   0.159[^b^](#t003fn003){ref-type="table-fn"}[\*\*\*](#t003fn007){ref-type="table-fn"}   11   4.54 ± 0.31   0.5[^b^](#t003fn003){ref-type="table-fn"}
  TA         25           3.85 ± 1.17                                                                                                                                    21    1.47 ± 1.25                                                                                                                                     21    7.58 ± 1.31                                                                                                                                                                             41   4.30 ± 0.68   
  AA         3            5.51 ± 0.51                                                                                                                                    3     3.44 ± 0.51                                                                                                                                     3     9.72 ± 0.45                                                                                                                                                                             49   4.41 ± 0.58   
  TT+TA      145          3.55 ± 1.41    0.01[^c^](#t003fn004){ref-type="table-fn"}[\*](#t003fn005){ref-type="table-fn"}   0.5[^c^](#t003fn004){ref-type="table-fn"}     119   1.20 ± 1.35   0.008[^c^](#t003fn004){ref-type="table-fn"}[\*](#t003fn005){ref-type="table-fn"}    0.4[^c^](#t003fn004){ref-type="table-fn"}     119   7.25 ± 1.42   0.003[^c^](#t003fn004){ref-type="table-fn"}[\*](#t003fn005){ref-type="table-fn"}   0.15[^c^](#t003fn004){ref-type="table-fn"}[\*\*\*](#t003fn007){ref-type="table-fn"}    52   4.44 ± 0.54   0.3[^c^](#t003fn004){ref-type="table-fn"}
  AA         3            5.51 ± 0.51                                                                                                                                    3     3.44 ± 0.51                                                                                                                                     3     9.72 ± 0.45                                                                                                                                                                             49   4.30 ± 0.63   
  TT         120          3.60 ± 1.28    0.1[^c^](#t003fn004){ref-type="table-fn"}                                         0.728[^c^](#t003fn004){ref-type="table-fn"}   98    1.11 ± 1.33   0.05[^c^](#t003fn004){ref-type="table-fn"}[\*\*](#t003fn006){ref-type="table-fn"}   0.795[^c^](#t003fn004){ref-type="table-fn"}   98    7.10 ± 1.39   0.02[^c^](#t003fn004){ref-type="table-fn"}[\*](#t003fn005){ref-type="table-fn"}    0.711[^c^](#t003fn004){ref-type="table-fn"}                                            11   4.50 ±0.31    0.4[^c^](#t003fn004){ref-type="table-fn"}
  TA+AA      28           4.02 ± 1.23                                                                                                                                    24    1.71 ± 1.35                                                                                                                                     24    7.84 ± 1.43                                                                                                                                                                             90   4.36 ± 0.63   
  TT+AA      123          3.65 ± 1.33    0.5[^c^](#t003fn004){ref-type="table-fn"}                                         0.995[^c^](#t003fn004){ref-type="table-fn"}   101   1.23 ± 1.37   0.4[^c^](#t003fn004){ref-type="table-fn"}                                           0.938[^c^](#t003fn004){ref-type="table-fn"}   101   7.22 ± 1.44   0.3[^c^](#t003fn004){ref-type="table-fn"}                                          0.88[^c^](#t003fn004){ref-type="table-fn"}                                             60   4.41 ± 0.58   0.5[^c^](#t003fn004){ref-type="table-fn"}
  TA         25           3.84 ± 1.17                                                                                                                                    21    1.47 ± 1.25                                                                                                                                     21    7.57 ± 1.31                                                                                                                                                                             41   4.35 ± 0.63   

PB, peripheral blood; SD, standard deviation; FDR, adjusted *P* value using false discovery rate controlling procedure

^a^Natural log transformation was applied to mobilization outcomes due to skewed distribution.

^b^Analysis of variance

Independent two-sample t-test

\*P\< 0.05

\*\*P = 0.05

\*\*\*P\< 0.2 after FDR adjustment

Univariate and multivariate analyses of host factors and mobilization outcomes {#sec011}
------------------------------------------------------------------------------

In univariate analysis, the circulating CD34+ cell count after mobilization was associated with sex, diagnosis, history of multiple chemotherapy regimens, and *RXFP4* genotype in the Korean population ([Table 4](#pone.0179986.t004){ref-type="table"}). In the European set, only a low BMI showed significant correlation with a low circulating CD34+ cell count (*P* \< 0.001). In the Korean set, the total CD34+ cell count/kg was associated with sex and *RXFP4* genotype, while the CD34+ cell count in a product was associated with sex, BMI, diagnosis, and *RXFP4* genotype.

10.1371/journal.pone.0179986.t004

###### Factors associated with mobilization outcomes in the univariate analysis[^a^](#t004fn001){ref-type="table-fn"}.
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  Variables                                                             Korean set    European set                                                                                                                                                                                                                                                                                           
  --------------------------------------------------------------------- ------------- ------------------------------------------------------------------------------------ ------------- ---------------------------------------------------------------------------------- ------------- ------------------------------------------------------------------------------------ ------------- ------------------------------------------------------------------------------------
  Age (yr)                                                              -0.064        0.4[^b^](#t004fn002){ref-type="table-fn"}                                            -0.014        0.9[^b^](#t004fn002){ref-type="table-fn"}                                          0.096         0.3[^b^](#t004fn002){ref-type="table-fn"}                                            0.007         0.9[^b^](#t004fn002){ref-type="table-fn"}
  Sex                                                                                 0.001[^c^](#t004fn003){ref-type="table-fn"}[\*](#t004fn006){ref-type="table-fn"}                   0.002[^c^](#t004fn003){ref-type="table-fn"}[\*](#t004fn006){ref-type="table-fn"}                 \<0.001[^c^](#t004fn003){ref-type="table-fn"}[\*](#t004fn006){ref-type="table-fn"}                 0.06[^c^](#t004fn003){ref-type="table-fn"}
   Male                                                                 3.99 ± 1.20                                                                                        1.87 ± 1.01                                                                                      7.70 ± 1.42                                                                                        4.47 ± 0.51   
   Female                                                               3.34 ± 1.19                                                                                        1.34 ± 0.77                                                                                      6.65 ± 1.19                                                                                        4.15 ± 0.78   
  Body-mass index (kg/m^2^)                                             0.155         0.06[^b^](#t004fn002){ref-type="table-fn"}                                           0.112         0.2[^b^](#t004fn002){ref-type="table-fn"}                                          0.204         0.02[^b^](#t004fn002){ref-type="table-fn"}[\*](#t004fn006){ref-type="table-fn"}      0.343         \<0.001[^b^](#t004fn002){ref-type="table-fn"}[\*](#t004fn006){ref-type="table-fn"}
  Diagnosis                                                                           \<0.001[^d^](#t004fn004){ref-type="table-fn"}[\*](#t004fn006){ref-type="table-fn"}                 0.08[^d^](#t004fn004){ref-type="table-fn"}                                                       0.01[^d^](#t004fn004){ref-type="table-fn"}[\*](#t004fn006){ref-type="table-fn"}      \-            
   Healthy donor                                                        3.88 ± 0.57                                                                                        1.74 ± 0.39                                                                                      6.81 ± 0.58                                                                                                      
   Acute leukemia                                                       2.07 ± 1.04                                                                                        0.81 ± 0.55                                                                                      6.16 ± 1.27                                                                                                      
   Non-Hodgkin lymphoma/sarcoma[^e^](#t004fn005){ref-type="table-fn"}   3.73 ± 1.68                                                                                        1.69 ± 1.22                                                                                      7.61 ± 1.05                                                                                                      
   Multiple myeloma                                                     3.87 ± 0.96                                                                                        1.67 ± 0.95                                                                                      7.61 ± 1.05                                                                                                      
  BM involvement of disease                                                           0.2[^c^](#t004fn003){ref-type="table-fn"}                                                          0.4[^c^](#t004fn003){ref-type="table-fn"}                                                        0.4[^c^](#t004fn003){ref-type="table-fn"}                                            \-            
   Absent                                                               3.80 ± 1.17                                                                                        1.69 ± 0.94                                                                                      7.16 ± 1.43                                                                                                      
   Present                                                              3.55 ± 1.35                                                                                        1.56 ± 0.96                                                                                      7.37 ± 1.40                                                                                                      
  Chemotherapy regimen history                                                        0.04[^c^](#t004fn003){ref-type="table-fn"}[\*](#t004fn006){ref-type="table-fn"}                    0.09[^c^](#t004fn003){ref-type="table-fn"}                                                       0.3[^c^](#t004fn003){ref-type="table-fn"}                                            \-            
   One or two regimens                                                  3.77 ± 1.22                                                                                        1.68 ± 0.95                                                                                      7.29 ± 1.41                                                                                                      
   Multiple regimens (three or more)                                    2.89 ± 1.27                                                                                        1.14 ± 0.85                                                                                      6.72 ± 1.52                                                                                                      
  Mobilization                                                                        0.8[^c^](#t004fn003){ref-type="table-fn"}                                                          0.9[^c^](#t004fn003){ref-type="table-fn"}                                                        0.7[^c^](#t004fn003){ref-type="table-fn"}                                            \-            
   G-CSF only                                                           3.69 ± 1.28                                                                                        1.64 ± 0.97                                                                                      7.30 ± 1.45                                                                                                      
   Chemotherapy and G-CSF                                               3.74 ± 1.20                                                                                        1.64 ± 0.93                                                                                      7.19 ± 1.40                                                                                                      
  *RXFP4* genotype                                                                    0.03[^d^](#t004fn004){ref-type="table-fn"}[\*](#t004fn006){ref-type="table-fn"}                    0.008[^d^](#t004fn004){ref-type="table-fn"}[\*](#t004fn006){ref-type="table-fn"}                 0.003[^d^](#t004fn004){ref-type="table-fn"}[\*](#t004fn006){ref-type="table-fn"}                   0.5[^d^](#t004fn004){ref-type="table-fn"}
   TT                                                                   3.60 ± 1.28                                                                                        1.11 ± 1.33                                                                                      7.10 ± 1.39                                                                                        4.54 ± 0.31   
   TA                                                                   3.85 ± 1.17                                                                                        1.47 ± 1.25                                                                                      7.58 ± 1.31                                                                                        4.30 ± 0.68   
   AA                                                                   5.51 ± 0.51                                                                                        3.44 ± 0.51                                                                                      9.72 ± 0.45                                                                                        4.41 ± 0.58   

^a^Natural log transformation was applied to mobilization outcomes due to skewed distribution. Data were represented as correlation coefficient (r) or mean ± standard deviation.

^b^Pearson correlation test

^c^Independent two-sample t-test

^d^Analysis of variance

^e^50 patients with non-Hodgkin lymphoma and one with sarcoma were included.

\**P* \< 0.05

Multivariate linear regression analysis revealed that female sex, diagnosis of acute leukemia, history of multiple chemotherapy regimens, and *RXFP4* genotype (TT and TA) remained independently associated with lower circulating CD34+ cell count after mobilization in the Korean set ([Table 5](#pone.0179986.t005){ref-type="table"}). Female sex and *RXFP4* genotype (TT and TA) showed consistent significance when analyzed with other outcome variables, i.e., total CD34+ cell count/kg and CD34+ cell count in a product.

10.1371/journal.pone.0179986.t005

###### Factors associated with log-transformed mobilization outcomes in the multivariate linear regression analysis in the Korean set.

![](pone.0179986.t005){#pone.0179986.t005g}

  Variables                                                             CD34+ cells/μL in PB      CD34+ cells/kg (×10^6^)                        CD34+ cells/μL in a product                                                                          
  --------------------------------------------------------------------- ------------------------- ---------------------------------------------- ----------------------------- -------------------------------------------- ------------------------- ----------------------------------------------
  Sex                                                                                                                                                                                                                                                 
   Male                                                                 Reference                                                                Reference                                                                  Reference                 
   Female                                                               -0.660 (-1.028, -0.292)   0.001[\*](#t005fn003){ref-type="table-fn"}     -0.630 (-1.018, -0.242)       0.002[\*](#t005fn003){ref-type="table-fn"}   -0.590 (-0.987, -0.193)   0.004[\*](#t005fn003){ref-type="table-fn"}
  Body-mass index (kg/m^2^)                                                                                                                                                                                                 0.025 (-0.031, 0.081)     0.4
  Diagnosis                                                                                                                                                                                                                                           
   Healthy donor                                                        Reference                                                                                                                                           Reference                 
   Acute leukemia                                                       -1.722 (-2.545, -0.898)   \<0.001[\*](#t005fn003){ref-type="table-fn"}                                                                              -1.737 (-2.574, -0.901)   \<0.001[\*](#t005fn003){ref-type="table-fn"}
   Non-Hodgkin lymphoma/sarcoma[^a^](#t005fn002){ref-type="table-fn"}   -0.259 (-0.701, 0.183)    0.2                                                                                                                       -0.368 (-0.803, 0.068)    0.09
   Multiple myeloma                                                     -0.057 (-0.551, 0.437)    0.8                                                                                                                       -0.150 (-0.653, 0.353)    0.6
  Chemotherapy regimen history                                                                                                                                                                                                                        
   Multiple regimens (three or more)                                    Reference                                                                                                                                                                     
   One or two regimens                                                  0.877 (0.100, 1.654)      0.03[\*](#t005fn003){ref-type="table-fn"}                                                                                                           
  *RXFP4* genotype                                                                                                                                                                                                                                    
   TT                                                                   Reference                                                                Reference                                                                  Reference                 
   TA                                                                   0.091 (-0.405, 0.588)     0.7                                            0.166 (-0.347, 0.678)         0.5                                          0.122 (-0.382, 0.626)     0.6
   AA                                                                   1.735 (0.446, 3.024)      0.009[\*](#t005fn003){ref-type="table-fn"}     1.809 (0.452, 3.166)          0.009[\*](#t005fn003){ref-type="table-fn"}   1.830 (0.526, 3.135)      0.006[\*](#t005fn003){ref-type="table-fn"}

PB, peripheral blood; CI, confidence interval

^a^50 patients with non-Hodgkin lymphoma and one with sarcoma were included.

\**P* \< 0.05

Discussion {#sec012}
==========

In this study, we found that rs11264422 genotype, located in the promoter flanking region of *RXFP4*, has a significant effect on HSC mobilization. The *RXFP4* gene encodes relaxin-3 receptor 2, which is a receptor for relaxin-3 and is expressed in various tissues including BM \[[@pone.0179986.ref033]\]. Relaxin-3 is a member of the insulin/relaxin superfamily of peptide hormones \[[@pone.0179986.ref034]\]. Segal *et al*. revealed that the relaxin hormone mobilizes BM-derived CD34+ endothelial progenitor cells into circulation, and their effect is mediated by the relaxin receptor \[[@pone.0179986.ref035]\]. The role of relaxin and its receptor-mediated pathway in HSC mobilization, as well as their association with the inter-individual variation of mobilization yield, can be hypothesized based on such observation.

The FDR-adjusted *P*-values for rs11264422 were above the significance threshold (*P* = 0.05). However, we considered *P* \< 0.2 after FDR adjustment as having a tendency for association. Given that the sample size was inadequate compared with the number of genes, we sought to find a possible exploratory factor. We determined three different mobilization outcomes and found consistent genes in all three. We then decided that the *P*-value of rs11264422 showed a meaningful trend, and wanted to suggest a further study. Therefore, we would like to conduct a confirmatory study using a larger number of patients.

The rs11264422 polymorphism has been associated with lower WBC counts in individuals of African, but not European, ancestry \[[@pone.0179986.ref028]\]. In our study, rs11264422 genotype was associated with HSC yield in Koreans but not in Europeans. Interestingly, the frequency of AA homozygote genotype is low in East Asians (1‒4% in Japanese and Chinese) and Africans (0.2%), but distinctly higher in Europeans (43%). Moreover, in a previous randomized controlled trial in Japan, a higher baseline WBC count was associated with a lower incidence of poor mobilization \[[@pone.0179986.ref036]\]. Therefore, we infer that the mechanism involved in HSC mobilization differs by ethnic groups, and rs11264422 genotype is associated with the HSC mobilization yield as well as the baseline WBC count in certain populations. Moreover, associations between the four polymorphisms in *CXCL12*, *VCAM1*, *CD44*, and *CSF3R* and mobilization outcome were not replicated in our study. Previous studies have already noted discrepancies in genetic associations, which were likely attributed to differences in ethnicity, diagnosis, number of study participants, and definition of outcome \[[@pone.0179986.ref013]--[@pone.0179986.ref017]\]. In particular, most of the previous studies had targeted those of European ancestry, whereas our study is the first to target the East Asian population. Therefore, our results suggest that there are significant differences in molecular mechanisms underlying HSC mobilization between different ethnic groups. Our preliminary data warrant further validation with larger cohorts of various population subgroups.

The therapeutic effect of circulating CD34+ cells has been demonstrated in hematologic disorders and cardiovascular diseases \[[@pone.0179986.ref037],[@pone.0179986.ref038]\]. In this context, the promotion of vasculogenesis is thought to be a mechanism for efficacy of CD34+ progenitor cells \[[@pone.0179986.ref019]\]. Notably, serelaxin, which is a recombinant human relaxin-2, has demonstrated significant treatment effects on acute heart failure in a recent clinical trial \[[@pone.0179986.ref039]\]. The potential mechanisms behind beneficial effects of serelaxin in acute heart failure include vasodilation, tissue healing from stimulation of angiogenesis and stem cell survival, and remodeling of the extracellular matrix \[[@pone.0179986.ref040]\]. Furthermore, a recent experimental study demonstrated that relaxin improves wound healing in diabetic mice \[[@pone.0179986.ref041]\]. In that study, the wound-healing effect of relaxin was disturbed by antibodies against vascular endothelial growth factor, CXCR4, and CXCR12 \[[@pone.0179986.ref041]\]. Our data support previous assumptions about the effects of relaxin on vasculogenic capacity and stem cell/progenitor cell regulation, and suggest a broader applicability of relaxin to other vascular disorders such as diabetes mellitus. In addition, our data also suggest that relaxin is a novel agent for the management of poor mobilizers.

Among host risk factors, female sex, history of multiple chemotherapy regimens, and diagnosis of acute leukemia remained independently associated with low circulating CD34+ cell counts in Koreans. Female sex \[[@pone.0179986.ref004],[@pone.0179986.ref042]\], prior treatment history \[[@pone.0179986.ref001]\], and diagnosis of acute leukemia \[[@pone.0179986.ref043]\] have all been known to be independent risk factors for poor mobilization. The mechanism behind association of sex and better mobilization potential can be explained by the stem cell regulation effect of sex steroids \[[@pone.0179986.ref044]\]. The contribution of an underlying hematologic disease on HSC mobilization can be explained by disease-related reduction of HSC reservoir, or chemotherapy-induced toxic effects on BM \[[@pone.0179986.ref043]\]. In the European set, only BMI correlated with circulating CD34+ cell counts. The mechanism behind association between higher BMI and better mobilization potential has been attributed to the effect of adipose tissue-containing HSCs, or a simple dose effect of G-CSF \[[@pone.0179986.ref008]\].

To the best of our knowledge, this is the first study to indicate an association between relaxin receptor polymorphism and HSC yield after mobilization. A potential limitation of our study is that the discovered locus is located in the regulatory region of *RXFP4*, and not in the protein-coding region. Further investigation regarding the functional effect of relaxin-3, as well as its receptor axis on the mobilization process, are required.

In conclusion, we found a novel association between relaxin receptor polymorphism and HSC yield after mobilization in ethnic Koreans. Our findings suggest an important functional role of relaxin axis during response of BM HSCs to the mobilizing agent. Results of our study give valuable insight to a potential therapeutic target---the relaxin---relaxin receptor axis---for the management of poor mobilizers, and for the treatment of various vascular diseases.
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